LACK OF A PHARMACOKINETIC (PK) INTERACTION BETWEEN ORAL MARIBAVIR, A NOVEL ANTI-CYTOMEGALOVIRUS AGENT, AND THE CYP 2C19 SUBSTRATE VORICONAZOLE, IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Downey, R. [1 ]
Johnson, J. [2 ]
Gelone, S. [2 ]
Broom, C. [2 ]
Villano, S. [2 ]
机构：
[1] Charles River Clin Serv NW Inc, Tacoma, WA USA
[2] ViroPharma Inc, Exton, PA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 17 条
  • [1] PHARMACOKINETIC INTERACTION BETWEEN RIFAMPIN AND ORAL MARIBAVIR, A NOVEL ANTI-CYTOMEGALOVIRUS AGENT, IN HEALTHY VOLUNTEERS
    Marbury, T.
    Johnson, J.
    Gelone, S.
    Broom, C.
    Villano, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S91 - S92
  • [2] PHARMACOKINETIC INTERACTION BETWEEN ORAL MARIBAVIR, A NOVEL ANTI-CYTOMEGALOVIRUS AGENT AND TACROLIMUS IN STABLE RENAL TRANSPLANT RECIPIENTS
    Pescovitz, M.
    Bloom, R.
    Pirsch, J.
    Johnson, J.
    Gelone, S.
    Broom, C.
    Villano, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S91 - S91
  • [3] PHARMACOKINETIC INTERACTION BETWEEN RANOLAZINE AND THE CYP2D6 SUBSTRATE METOPROLOL IN HEALTHY VOLUNTEERS
    Wang, Xuegong
    Bingham, Justus
    Devault, Arthur
    Stachr, Peter
    Belardinelli, Luiz
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1107 - 1107
  • [4] A Pharmacokinetic Model of Drug-Drug Interaction between Clopidogrel and Omeprazole at CYP 2C19 in Humans
    Tangamornsuksan, Wimonchat
    Thiansupornpong, Pongpak
    Morasuk, Thirawut
    Lohitnavy, Ornrat
    Lohitnavy, Manupat
    2017 39TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2017, : 2704 - 2707
  • [5] CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects
    Zhu, Li
    Bruggemann, Roger J.
    Uy, Jonathan
    Colbers, Angela
    Hruska, Matthew W.
    Chung, Ellen
    Sims, Karen
    Vakkalagadda, Blisse
    Xu, Xiaohui
    van Schaik, Ron H. N.
    Burger, David M.
    Bertz, Richard J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (02): : 235 - 246
  • [6] THE EFFECT OF CYP2C19 POLYMORPHISM ON THE PHARMACOKINETICS AND TOLERABILITY OF VORICONAZOLE AFTER MULTIPLE ORAL ADMINISTRATIONS IN HEALTHY VOLUNTEERS.
    Lee, S.
    Kim, B. H.
    Nam, W. S.
    Kim, S. J.
    Shim, J. H.
    Yoon, S. H.
    Cho, J. Y.
    Shin, S. G.
    Jang, I. J.
    Yu, K. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S26 - S27
  • [7] Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers
    Sheng, Yu-Cheng
    Wang, Kun
    He, Ying-Chun
    Yang, Juan
    Zheng, Qing-Shan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (11) : 1165 - 1169
  • [8] Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers
    Yu-Cheng Sheng
    Kun Wang
    Ying-Chun He
    Juan Yang
    Qing-Shan Zheng
    European Journal of Clinical Pharmacology, 2010, 66 : 1165 - 1169
  • [9] Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers
    Teng, Renli
    Mitchell, Patrick
    Butler, Kathleen
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (04) : 305 - 312
  • [10] Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction between Voriconazole and Tacrolimus Using Physiologically- Based Pharmacokinetic Modelling
    Jin, Zhi-Ping
    Yan, Miao
    Li, Si-Ze
    Wang, Bao-Qing
    Xu, Qing
    Wu, Wei
    Li, Xiao-Yu
    Lv, Qian-Zhou
    Xiang, Xiao-Qiang
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 59
12